Design and synthesis of norendoxifen analogues with dual aromatase inhibitory and estrogen receptor modulatory activities

Journal of Medicinal Chemistry

Volumn 58, Issue 6, 2015, Pages 2623-2648

  Lv, Wei ^a   Liu, Jinzhong ^b   Skaar, Todd C ^b   Flockhart, David A ^b   Cushman, Mark ^a  

^a PURDUE UNIVERSITY   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(4 (2 BROMOETHOXY)PHENYL)(4 NITROPHENYL)METHANONE; (4 HYDROXYPHENYL)(4 NITROPHENYL)METHANONE; (4 METHOXYPHENYL)(4 NITROPHENYL)METHANONE; 2 (4 (1,2 DIPHENYLBUT 1 EN 1 YL)PHENOXY)ACETAMIDE; 2 (4 (1,2 DIPHENYLBUT 1 EN 1 YL)PHENOXY)ETHAN 1 AMINE; 2 (4 (2 (4 FLUOROPHENYL) 1 (4 HYDROXYPHENYL)BUT 1 EN 1 YL)PHENOXY)ACETAMIDE; 2 (4 (2 ETHYL 1 (4 HYDROXYPHENYL)BUT 1 EN 1 YL)PHENOXY)ACETAMIDE; 4 (1 (4 (2 AMINO 2 OXOETHOXY)PHENYL) 1 (4 HYDROXYPHENYL)BUT 1 EN 2 YL)PHEYNYL PIVALATE; 4 (1 (4 (2 AMINOETHOXY)PHENYL) 1 (4 AMINOPHENYL)BUT 1EN 2 YL)PHENOL; 4 (1 (4 (2 AMINOETHOXY)PHENYL) 2 (4 FLUOROPHENYL)BUT 1EN 1 YL)PHENOL; 4 (1 (4 (2 AMINOETHOXY)PHENYL) 2 ETHYLBUT 1 EN 1 YL)PHENOL; 4 (1 (4 (2 AMINOETHOXY)PHENYL) 2 PHENYLBUT 1 EN 1 YL)ANILINE; 4 (1 (4 (2 BROMOETHOXY)PHENYL) 2 PHENYLBUT 1 EN 1 YL)ANILINE; 4 (1 (4 AMINOPHENYL) 1 (4 (2 BROMOETHOXY)PHENYL)BUT 1EN 2 YL)PHENYL PIVALATE; 4 (1,2 DIPHENYLBUT 1 EN 1 YL)PHENOL; 4' HYDROXYNORENDOXIFEN; 4,4' (1 (4 (2 AMINOETHOXY)PHENYL)BUT 1 ENE 1,2 DIYL) DIPHENOL; 4,4' (2 (4 FLUOROPHENYL)BUT 1 ENE 1,1 DIYL)DIPHENOL; 4,4' (2 ETHYLBUT 1 ENE 1,1 DIYL)DIPHENOL; 4,4' (2 PHENYLPENT 1 ENE 1,1 DIYL)DIPHENOL; 4,4' (2 PHENYLPROP 1 ENE 1,1 DIYL)DIPHENOL; 4,4' (2,2 DIPHENYLETHENE 1,1 DIYL)DIPHENOL; 4,4' (3 METHYL 2 PHENYLBUT 1 ENE 1,1 DIYL)DIPHENOL; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; CYTOCHROME P450; NORENDOXIFEN DERIVATIVE; PYRROLIDINE DERIVATIVE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; AROMATASE; ESTROGEN RECEPTOR; N,N-DIDESMETHYL-4-HYDROXYTAMOXIFEN; TAMOXIFEN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOLOGICAL ACTIVITY; BREAST CANCER; CROSS COUPLING REACTION; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MOLECULAR DYNAMICS; MOLECULAR MODEL; STEREOCHEMISTRY; ANALOGS AND DERIVATIVES; BREAST NEOPLASMS; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; HUMAN; MCF 7 CELL LINE; METABOLISM; SIGNAL TRANSDUCTION; SYNTHESIS;

ANTINEOPLASTIC AGENTS; AROMATASE; AROMATASE INHIBITORS; BREAST NEOPLASMS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG DESIGN; HUMANS; MCF-7 CELLS; MODELS, MOLECULAR; RECEPTORS, ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SIGNAL TRANSDUCTION; TAMOXIFEN;

EID: 84925872644     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm501218e     Document Type: Article

References (51)

1. Breast Cancer Facts & Figures 2013-2014; American Cancer Society, Inc: Atlanta, GA, 2013.
2. Cancer Facts & Figures 2013; American Cancer Society, Inc.: Atlanta, GA, 2013.
3. Clarke, M.; Collins, R.; Davies, C.; Godwin, J.; Gray, R.; Peto, R. Early Breast Cancer Trialists Collaborative, G. Tamoxifen for Early Breast Cancer: An Overview of the Randomised Trials Lancet 1998, 351, 1451-1467
4. Fisher, B.; Costantino, J. P.; Wickerham, D. L.; Redmond, C. K.; Kavanah, M.; Cronin, W. M.; Vogel, V.; Robidoux, A.; Dimitrov, N.; Atkins, J.; Daly, M.; Wieand, S.; Tan-Chiu, E.; Ford, L.; Wolmark, N. Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study J. Natl. Cancer Inst. 1998, 90, 1371-1388
5. Ali, S.; Coombes, R. C. Endocrine-Responsive Breast Cancer and Strategies for Combating Resistance Nature Rev. Cancer 2002, 2, 101-112
6. Santen, R. J. Long Term Tamoxifen Therapy: Can an Antagonist Become an Agonist? J. Clin. Endocrinol. Metab. 1996, 81, 2027-2029
7. Bonneterre, J.; Buzdar, A.; Nabholtz, J. M. A.; Robertson, J. F. R.; Thurlimann, B.; von Euler, M.; Sahmoud, T.; Webster, A.; Steinberg, M.; Armidex Writing Committee on behalf of the Investigators Committee Members Anastrozole is Superior to Tamoxifen as First-Line Therapy in Hormone Receptor Positive Advanced Breast Carcinoma-Results of Two Randomized Trials Designed for Combined Analysis Cancer 2001, 92, 2247-2258
8. Mouridsen, H.; Gershanovick, M.; Sun, Y.; Perez-Carrion, R.; Boni, C.; Monnier, A.; Apffelstaedt, J.; Smith, R.; Sleeboom, H. P.; Jaenicke, F.; Pluzanska, A.; Dank, M.; Becquart, D.; Bapsy, P. P.; Salminen, E.; Snyder, R.; Chaudri-Ross, H.; Lang, R.; Wyld, P.; Bhatnagar, A. Phase III Study of Letrozole Versus Tamoxifen as First-Line Therapy of Advanced Breast Cancer in Postmenopausal Women: Analysis of Survival and Update of Efficacy from the International Letrozole Breast Cancer Group J. Clin. Oncol. 2003, 21, 2101-2109
9. Howell, A.; Cuzick, J.; Baum, M.; Buzdar, A.; Dowsett, M.; Forbes, J. F.; Hoctin-Boes, G.; Houghton, I.; Locker, G. Y.; Tobias, J. S.; Grp, A. T. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) Trial after Completion of 5 Years Adjuvant Treatment for Breast Cancer Lancet 2005, 365, 60-62
10. Thurlimann, B.; Keshaviah, A.; Coates, A. S.; Mouridsen, H.; Mauriac, L.; Forbes, J. F.; Paridaens, R.; Castiglione-Gertsch, M.; Gelber, R. D.; Rabaglio, M.; Smith, I.; Wardly, A.; Price, K. N.; Goldhirsch, A.; The Breast International Group (BIG) 1-98 Collaborative Group A Comparison of Letrozole and Tamoxifen in Postmenopausal Women with Early Breast Cancer N. Engl. J. Med. 2005, 353, 2747-2757
11. Williams, N. Effect of Anastrozole and Tamoxifen as Adjuvant Treatment for Early-Stage Breast Cancer: 100-Month Analysis of the ATAC Trial Lancet Oncol. 2008, 9, 45-53
12. Heshmati, H. M.; Khosla, S.; Robins, S. P.; OFallon, W. M.; Melton, L. J.; Riggs, B. L. Role of Low Levels of Endogenous Estrogen in Regulation of Bone Resorption in Late Postmenopausal Women J. Bone Miner. Res. 2002, 17, 172-178
13. Ewer, M. S.; Gluck, S. A Womans Heart. The Impact of Adjuvant Endocrine Therapy on Cardiovascular Health Cancer 2009, 115, 1813-1826
14. Bird, B. R. J. H.; Swain, S. M. Cardiac Toxicity in Breast Cancer Survivors: Review of Potential Cardiac Problems Clin. Cancer Res. 2008, 14, 14-24
15. Bundred, N. J. The Effects of Aromatase Inhibitors on Lipids and Thrombosis Br. J. Cancer 2005, 93, S23-S27
16. Khan, Q. J.; ODea, A. P.; Sharma, P. Musculoskeletal Adverse Events Asociated with Adjuvant Aromatase Inhibitors J. Oncol. 2010, 654348 10.1155/2010/654348
17. Jelovac, D.; Macedo, L.; Goloubeva, O. G.; Handratta, V.; Brodie, A. M. H. Additive Antitumor Effect of Aromatase Inhibitor Letrozole and Antiestrogen Fulvestrant in a Postmenopausal Breast Cancer Model Cancer Res. 2005, 65, 5439-5444
18. Baum, M.; Buzdar, A. U.; Cuzick, J.; Forbes, J.; Houghton, J.; Klijn, J. G. M.; Sahmoud, T.; Grp, A. T. Anastrozole Alone or in Combination with Tamoxifen Versus Tamoxifen Alone for Adjuvant Treatment of Postmenopausal Women with Early Breast Cancer: First Results of the ATAC Randomised Trial Lancet 2002, 359, 2131-2139
19. Lu, W. J.; Xu, C.; Pei, Z. F.; Mayhoub, A. S.; Cushman, M.; Flockhart, D. A. The Tamoxifen Metabolite Norendoxifen Is a Potent and Selective Inhibitor of Aromatase (CYP19) and a Potential Lead Compound for Novel Therapeutic Agents Breast Cancer Res. Treat. 2012, 133, 99-109
20. Lv, W.; Liu, J.; Lu, D.; Flockhart, D. A.; Cushman, M. Synthesis of Mixed (E, Z)-, (E)-, and (Z)-Norendoxifen with Dual Aromatase Inhibitory and Estrogen Receptor Modulatory Activities J. Med. Chem. 2013, 56, 4611-4618
21. Ghosh, D.; Lo, J.; Morton, D.; Valette, D.; Xi, J.; Griswold, J.; Hubbell, S.; Egbuta, C.; Jiang, W.; An, J.; Davies, H. M. L. Novel Aromatase Inhibitors by Structure-Guided Design J. Med. Chem. 2012, 55, 8464-8476
22. Shiau, A. K.; Barstad, D.; Loria, P. M.; Cheng, L.; Kushner, P. J.; Agard, D. A.; Greene, G. L. The Structural Basis of Estrogen Receptor/Coactivator Recognition and the Antagonism of This Interaction by Tamoxifen Cell 1998, 95, 927-937
23. Favia, A. D.; Nicolotti, O.; Stefanachi, A.; Leonetti, F.; Carotti, A. Computational Methods for the Design of Potent Aromatase Inhibitors Expert Opin. Drug Discovery 2013, 8, 395-409
24. Nguyen, A.; Top, S.; Pigeon, P.; Vessieres, A.; Hillard, E. A.; Plamont, M. A.; Huche, M.; Rigamonti, C.; Jaouen, G. Synthesis and Structure-Activity Relationships of Ferrocenyl Tamoxifen Derivatives with Modified Side Chains Chem.-Eur. J. 2009, 15, 684-696
25. Lu, W. J.; Desta, Z.; Flockhart, D. A. Tamoxifen Metabolites as Active Inhibitors of Aromatase in the Treatment of Breast Cancer Breast Cancer Res. Treat. 2012, 131, 473-481
26. Davies, H. M. L.; Nagashima, T.; Klino, J. L. Stereoselectivity of Methyl Aryldiazoacetate Cyclopropanations of 1,1-Diarylethylene. Asymmetric Aynthesis of a Cyclopropyl Analogue of Tamoxifen Org. Lett. 2000, 2, 823-826
27. Canne, L. E.; Winston, R. L.; Kent, S. B. H. Synthesis of a Versatile Purification Handle for Use with Boc Chemistry Solid Phase Peptide Synthesis Tetrahedron Lett. 1997, 38, 3361-3364
28. Ruenitz, P. C.; Bourne, C. S.; Sullivan, K. J.; Moore, S. A. Estrogenic Triarylethylene Acetic Acids: Effect of Structural Variation on Estrogen Receptor Affinity and Estrogenic Potency and Efficacy in MCF-7 Cells J. Med. Chem. 1996, 39, 4853-4859
29. Liu, J.; Lu, D.; Lu, J.; Lv, W.; Cushman, M.; Desta, Z.; Flockhart, D. A. Hydroxynorendoxifen, an Active Tamoxifen Metabolite, Possesses Dual Aromatase Inhibitory and Estrogen Receptor Modulatory Activities Clin. Pharmacol. Ther. 2014, 95, S21-S21
30. Liu, J. Z.; Flockhart, P. J.; Lu, D. S.; Lv, W.; Lu, W. J. J.; Han, X.; Cushman, M.; Flockhart, D. A. Inhibition of Cytochrome P450 Enzymes by the E-and Z -Isomers of Norendoxifen Drug Metab. Dispos. 2013, 41, 1715-1720
31. Gauthier, S.; Mailhot, J.; Labrie, F. New Highly Stereoselective Synthesis of (Z)-4-Hydroxytamoxifen and (Z)-4-Hydroxytoremifene via McMurry Reaction J. Org. Chem. 1996, 61, 3890-3893
32. Brzozowski, A. M.; Pike, A. C. W.; Dauter, Z.; Hubbard, R. E.; Bonn, T.; Engstrom, O.; Ohman, L.; Greene, G. L.; Gustafsson, J. A.; Carlquist, M. Molecular Basis of Agonism and Antagonism in the Oestrogen Receptor Nature 1997, 389, 753-758
33. Jordan, V. C. Antiestrogens and Selective Estrogen Receptor Modulators as Multifunctional Medicines. 1. Receptor Interactions J. Med. Chem. 2003, 46, 883-908
34. Jordan, V. C.; Lieberman, M. E.; Cormier, E.; Koch, R.; Bagley, J. R.; Ruenitz, P. C. Structural Requirements for the Pharmacological Activity of Nonsteroidal Antiestrogens In Vitro Mol. Pharmacol. 1984, 26, 272-278
35. Levenson, A. S.; Jordan, V. C. The Key to the Antiestrogenic Mechanism of Raloxifene Is Amino Acid 351 (Aspartate) in the Estrogen Receptor Cancer Res. 1998, 58, 1872-1875
36. Schafer, J. M.; Liu, H.; Bentrem, D. J.; Zapf, J. W.; Jordan, V. C. Allosteric Silencing of Activating Function 1 in the 4-Hydroxytamoxifen Estrogen Receptor Complex Is Induced by Substituting Glycine for Aspartate at Amino Acid 351 Cancer Res. 2000, 60, 5097-5105
37. Lim, Y. C.; Desta, Z.; Flockhart, D. A.; Skaar, T. C. Endoxifen (4-Hydroxy- N -desmethyl-tamoxifen) Has Anti-estrogenic Effects in Breast Cancer Cells with Potency Similar to 4-Hydroxy-tamoxifen Cancer Chemother. Pharmacol. 2005, 55, 471-478
38. Miquel, J. F. 1,1-Bis(p -hydroxyphenyl)-2,2-diethylethylene, a New Isomer of Stilbestrol Acta Chem. Scand. 1958, 12, 274-280
39. Shiina, I.; Sano, Y.; Nakata, K.; Suzuki, M.; Yokoyama, T.; Sasaki, A.; Orikasa, T.; Miyamoto, T.; Ikekita, M.; Nagahara, Y.; Hasome, Y. An Expeditious Synthesis of Tamoxifen, a Representative SERM (Selective Estrogen Receptor Modulator), via the Three-Component Coupling Reaction Among Aromatic Aldehyde, Cinnamyltrimethylsilane, and β-Chlorophenetole Bioorg. Med. Chem. 2007, 15, 7599-7617
40. Stanciuc, O.; Balaban, A. T. Reaction of Pyrylium Salts with Nucleophiles. 23: Triarylethene Derivatives Containing an Oxyalkyleneamino or Oxyalkylene- N- pyridinium Side Chain J. Pharm. Sci. 1993, 82, 927-933
41. Bao, X. F.; Lu, S. Y.; Liow, J. S.; Zoghbi, S. S.; Jenko, K. J.; Clark, D. T.; Gladding, R. L.; Innis, R. B.; Pike, V. W. Radiosynthesis and Evaluation of an F-18-Labeled Positron Emission Tomography (PET) Radioligand for Brain Histamine Subtype-3 Receptors Based on a Nonimidazole 2-Aminoethylbenzofuran Chemotype J. Med. Chem. 2012, 55, 2406-2415
42. Lubczyk, V.; Bachmann, H.; Gust, R. Investigations on Estrogen Receptor Binding. The Estrogenic, Antiestrogenic, and Cytotoxic Properties of C2-Alkyl-Substituted 1,1-Bis(4-hydroxyphenyl)-2-phenylethenes J. Med. Chem. 2002, 45, 5358-5364
43. Forman, B.; Yu, D. Compounds and Methods for Treating Breast Cancer and Other Diseases. U.S. Pat. Appl. Publ. US 2005/0096384 A1, 2005.
44. Duan, X. F.; Zeng, J.; Lu, J. W.; Zhang, Z. B. Insights into the General and Efficient Cross McMurry Reactions between Ketones J. Org. Chem. 2006, 71, 9873-9876
45. Katzenellenbogen, J. A.; Tatee, T.; Robertson, D. W. Preparation of Tritium-Labeled 4-Hydroxy-α-[ p -(2-(N -pyrrolidinyl)ethoxy)phenyl]-α′-nitrostilbene (CN-928), a Biologically Important Metabolite of the Antiestrogen CI-628 J. Labelled Compd. Radiopharm. 1981, 18, 865-879
46. Kim, S. H.; Katzenellenbogen, J. A. Triarylethylene Bisphenols with a Novel Cycle Are Ligands for the Estrogen Receptor Bioorg. Med. Chem. 2000, 8, 785-793
47. Burke, P. J.; Koch, T. H. Design, Synthesis, and Biological Evaluation of Doxorubicin-Formaldehyde Conjugates Targeted to Breast Cancer Cells J. Med. Chem. 2004, 47, 1193-1206
48. Ali, S. M.; Ahmad, A.; Shahabuddin, S.; Ahmad, M. U.; Sheikh, S.; Ahmad, I. Endoxifen is a New Potent Inhibitor of PKC: A Potential Therapeutic Agent for Bipolar Disorder Bioorg. Med. Chem. Lett. 2010, 20, 2665-2667
49. Fausett, B. W.; Liebeskind, L. S. Palladium-Catalyzed Coupling of Thiol Esters with Aryl and Primary and Secondary Alkyl Organoindium Reagents J. Org. Chem. 2005, 70, 4851-4853
50. Prakash, G. K. S.; Panja, C.; Mathew, T.; Olah, G. A. BF3-H2O catalyzed Fries Rearrangement of Phenolic Esters Catal. Lett. 2007, 114, 24-29
51. Lu, W. J.; Ferlito, V.; Xu, C.; Flockhart, D. A.; Caccamese, S. Enantiomers of Naringenin as Pleiotropic, Stereoselective Inhibitors of Cytochrome P450 Isoforms Chirality 2011, 23, 891-896